Desmopressin melt improves response and compliance compared with tablet in treatment of primary monosymptomatic nocturnal enuresis.

Juul KV, Van Herzeele C, De Bruyne P, Goble S, Walle JV, Nørgaard JP

European journal of pediatrics16 May 2013Cited by 24 (Europe PMC)

PMID23677249PMCIDPMC3742424DOI10.1007/s00431-013-1992-9PepBankPUB-23677249

Summary

UnlabelledPrimary nocturnal enuresis is a prevalent childhood condition that can persist into adulthood. Desmopressin is an antidiuretic available as orally disintegrating lyophilisate (melt) or solid tablet. Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt and tablet motivated a post hoc analysis of a previously reported randomised, crossover study. The efficacy of desmopressin melt compared with tablet was evaluated using the International Children's Continence Society (ICCS) responder definitions. Compliance was further analysed using detailed criteria, and the association between efficacy and compliance was examined. In total, 221 patients aged 5-15 years, already receiving desmopressin tablets were randomised to the treatment sequence melt (120/240 μg)/tablet (0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods. The probability of being a responder (partial or full) during either period was significantly more likely with desmopressin melt compared with tablet (odds ratio, 2.0; confidence intervals, 1.07-3.73; p = 0.03). There was no period effect on compliance in the tablet/melt sequence and no difference in the number of completely compliant patients in each formulation group; however, more patients were >75 % compliant in period 1 compared with period 2 in the melt/tablet sequence. Increased compliance was associated with greater reductions in the number of wet nights for both formulations.ConclusionsDesmopressin melt, compared with tablet, improves the probability of being a responder. Switching from tablet to melt formulation increased patient compliance. Increased compliance was associated with increased efficacy. Switching to desmopressin melt may benefit patients with suboptimal responses to desmopressin tablet.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with enuresis, desmopressin melt increased response odds versus tablet (odds ratio 2.0, confidence intervals 1.07-3.73, p = 0.03).
In plain wordsIn children with enuresis, desmopressin melt increased response odds compared with tablet.
Peptide
Desmopressin
Outcome
IncreasePartial or full response
Study
n = 221
Comparator
Desmopressin tablet
Outcome group
Enuresis · Kidney and urinary
Studied dose
melt 120/240 μg or tablet 0.2/0.4 mg · oral · 3 weeks per periodAs given in this study (human).
Measurements
Odds ratio of partial or full response, melt versus tablet
2 odds ratio
desmopressin melt versus tablet, crossover
95% confidence interval of odds ratio
1.07 to 3.73 odds ratio
desmopressin melt versus tablet, crossover
Source sentences
Summary
The probability of being a responder (partial or full) during either period was significantly more likely with desmopressin melt compared with tablet (odds ratio, 2.0; confidence intervals, 1.07-3.73; p = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt and tablet motivated a post hoc analysis of a previously reported randomised, crossover study.
Summary · context
In total, 221 patients aged 5-15 years, already receiving desmopressin tablets were randomised to the treatment sequence melt (120/240 μg)/tablet (0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods.
Show in the study text Report a problemFND-2367724901
02HumanRandomized controlled trialOther
In children with enuresis, complete compliance did not differ between desmopressin formulations.
In plain wordsIn children with enuresis, complete compliance did not differ between desmopressin melt and tablet.
Peptide
Desmopressin
Outcome
No significant changeComplete compliance
Study
n = 221
Comparator
Desmopressin tablet
Outcome group
Treatment adherence and retention · Whole body
Studied dose
melt 120/240 μg or tablet 0.2/0.4 mg · oral · 3 weeks per periodAs given in this study (human).
Source sentences
Summary
no difference in the number of completely compliant patients in each formulation group
2 context sentences(design, population, supporting numbers)
Summary · context
Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt and tablet motivated a post hoc analysis of a previously reported randomised, crossover study.
Summary · context
In total, 221 patients aged 5-15 years, already receiving desmopressin tablets were randomised to the treatment sequence melt (120/240 μg)/tablet (0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods.
Show in the study text Report a problemFND-2367724903
03HumanRandomized controlled trialOther
In children with enuresis, desmopressin compliance showed no period effect in the tablet/melt sequence.
In plain wordsIn children with enuresis, desmopressin compliance did not differ between periods in the tablet/melt sequence.
Peptide
Desmopressin
Outcome
No significant changePeriod effect on compliance
Study
n: not reported in source
Comparator
Other treatment period in tablet/melt sequence
Outcome group
Treatment adherence and retention · Whole body
Studied dose
melt 120/240 μg or tablet 0.2/0.4 mg · oral · 3 weeks per periodAs given in this study (human).
Source sentences
Summary
There was no period effect on compliance in the tablet/melt sequence
2 context sentences(design, population, supporting numbers)
Summary · context
Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt and tablet motivated a post hoc analysis of a previously reported randomised, crossover study.
Summary · context
In total, 221 patients aged 5-15 years, already receiving desmopressin tablets were randomised to the treatment sequence melt (120/240 μg)/tablet (0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods.
Show in the study text Report a problemFND-2367724902
04HumanRandomized controlled trialOther
In children with enuresis, more patients exceeded 75% compliance in period 1 than period 2 of the desmopressin melt/tablet sequence.
In plain wordsIn children with enuresis, compliance above 75% was more frequent in period 1 than period 2 of the desmopressin melt/tablet sequence.
Peptide
Desmopressin
Outcome
IncreaseCompliance above 75%
Study
n: not reported in source
Comparator
Period 2 in melt/tablet sequence
Outcome group
Treatment adherence and retention · Whole body
Studied dose
melt 120/240 μg or tablet 0.2/0.4 mg · oral · 3 weeks per periodAs given in this study (human).
Source sentences
Summary
however, more patients were >75 % compliant in period 1 compared with period 2 in the melt/tablet sequence.
2 context sentences(design, population, supporting numbers)
Summary · context
Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt and tablet motivated a post hoc analysis of a previously reported randomised, crossover study.
Summary · context
In total, 221 patients aged 5-15 years, already receiving desmopressin tablets were randomised to the treatment sequence melt (120/240 μg)/tablet (0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods.
Show in the study text Report a problemFND-2367724904
05HumanObservational studyOther
In children with enuresis, greater compliance was associated with greater wet-night reductions for both desmopressin formulations.
In plain wordsIn children with enuresis, greater desmopressin compliance was linked to greater reductions in wet nights for both formulations.
Peptide
Desmopressin
Outcome
DecreaseCompliance and wet-night reduction
Study
n = 221
Outcome group
Enuresis · Kidney and urinary
Studied dose
melt 120/240 μg or tablet 0.2/0.4 mg · oral · 3 weeks per periodAs given in this study (human).
Source sentences
Summary
Increased compliance was associated with greater reductions in the number of wet nights for both formulations.
2 context sentences(design, population, supporting numbers)
Summary · context
Recent findings suggesting different food interactions and clinical characteristics, including compliance, between desmopressin melt and tablet motivated a post hoc analysis of a previously reported randomised, crossover study.
Summary · context
In total, 221 patients aged 5-15 years, already receiving desmopressin tablets were randomised to the treatment sequence melt (120/240 μg)/tablet (0.2/0.4 mg) or tablet/melt in two consecutive 3-week periods.
Show in the study text Report a problemFND-2367724905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.